Evercore ISI is adding Edwards Lifesciences (EW) to the firm’s “Tactical Outperform” list as the firm argues that the recent selloff in shares “seems overdone.” The upcoming TCT presentation should reinforce confidence in TAVR’s performance against SAVR over seven years, according to the analyst, who has an Outperform rating and $88 price target on Edwards shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Gold tops $4,000, SoftBank buys robotics unit: Morning Buzz
- Intel, FedEx downgraded: Wall Street’s top analyst calls
- Oppenheimer downgrades Edwards Lifesciences on long-range plan concerns
- Edwards Lifesciences downgraded to Perform from Outperform at Oppenheimer
- Netflix upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls